Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Next quarterly earnings (projected) on January 13, 2027, a projected date rather than a confirmed one. There are 5 upcoming events on record.
Cash runway is approximately 30 months based on the most recent reported cash position and quarterly operating burn as of 2026-08-31.
| Date | Event | Type | Phase |
|---|---|---|---|
| January 13, 2027 est. | Next quarterly earnings (projected) | Earnings | — |
| January 15, 2027 | A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Trial Milestone | Phase 1 |
| January 15, 2028 | A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) | Trial Milestone | Phase 2 |
| October 15, 2029 | Study of NX-5948 Versus Pirtobrutinib in R/R CLL/SLL | Trial Milestone | Phase 3 |
| May 15, 2033 | Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies | Trial Milestone | Phase 1/Phase 2 |
Track NRIX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open NRIX in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.